Effect of Decoction for Clearing Liver and Removing Dampness Activating Blood Circulation on the Efficacy and Liver Function Indicators of Non-Alcoholic Fatty Liver Disease
DOI: 10.23977/medcm.2024.060101 | Downloads: 9 | Views: 255
Author(s)
Guoxiang Liu 1, Zhichao Wang 2, Xiaohui Zhang 3, Sreemoy Kanti Das 1
Affiliation(s)
1 Faculty of Pharmacy, Lincoln University College, Petaling Jaya, Selangor, Malaysia
2 Department of Medicine, Lincoln University College, Petaling Jaya, Selangor, Malaysia
3 Department of Rehabilitation Medicine, Heilongjiang Nursing College, Harbin, Heilongjiang, China
Corresponding Author
Sreemoy Kanti DasABSTRACT
Traditional studies have not covered the comprehensive study of decoction for clearing liver and removing dampness activating blood circulation (CLRDA) on non-alcoholic fatty liver, lacking standard treatment or comparison between placebo group and decoction for CLRDA, which challenges the credibility of the conclusions. This study used the "decoction for CLRDA" formula to treat non-alcoholic fatty liver disease (NAFLD), using a randomized controlled trial. This article divides patients into multiple groups, with the treatment group receiving a specific combination of traditional Chinese medicine (TCM), and the control group receiving other TCM treatments. During the treatment period, regular follow-up monitoring is conducted, and this article records patient demographics, clinical symptoms, and liver function indicators. The data analysis uses t-value test and p-value test to compare the differences between two groups, ensuring the reliability of the results. During the treatment process, the "decoction for CLRDA" group achieved significant success in liver function indicators. Specific data showed that after treatment, the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were significantly reduced. The t-value is -7.83 and the p-value is 0.014, indicating a statistically significant difference compared to the control group. This strongly supports the efficacy of "decoction for CLRDA" in treating NAFLD.
KEYWORDS
Decoction for CLRDA, Non-Alcoholic Fatty Liver, Randomized Controlled Trial, AST and ALTCITE THIS PAPER
Guoxiang Liu, Zhichao Wang, Xiaohui Zhang, Sreemoy Kanti Das, Effect of Decoction for Clearing Liver and Removing Dampness Activating Blood Circulation on the Efficacy and Liver Function Indicators of Non-Alcoholic Fatty Liver Disease. MEDS Chinese Medicine (2024) Vol. 6: 1-8. DOI: http://dx.doi.org/10.23977/medcm.2024.060101.
REFERENCES
[1] Guan Yuhong. Analysis of the effect of liver cleansing, dampening and activating blood decoction combined with liver-protecting and enzyme-lowering drugs in the treatment of alcoholic liver disease . Database of Chinese Scientific and Technological Journals (Abstract Edition) Medicine and Health, 2019,31(07): 00118-00118.
[2] Nan Ran, Li Yixuan. Effect of Qinghe, dampening and activating blood decoction combined with Silymarin capsules on the index of liver fibrosis in patients with alcoholic liver disease . Journal of Practical Medicine, 2022, 38(8): 1022-1026.
[3] Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver International, 2022, 42(9): 1955-1968.
[4] Attia S L, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD/NASH. Clinical and Translational Science, 2021, 14(1): 11-19.
[5] Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, et al. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chinese Medicine, 2021, 16(1): 1-17.
[6] Mundi M S, Velapati S, Patel J, Kellogg T A, Dayyeh B K A, Hurt M R T. Evolution of NAFLD and its management. Nutrition in Clinical Practice, 2020, 35(1): 72-84.
[7] Zhou J, Zhou F, Wang W, Zhang W, Ji X J, Zhang Y X, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020, 71(5): 1851-1864.
[8] Ferguson D, Finck B N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology, 2021, 17(8): 484-495.
[9] Targher G, Byrne C D, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020, 69(9): 1691-1705.
Downloads: | 4221 |
---|---|
Visits: | 167196 |
Sponsors, Associates, and Links
-
MEDS Clinical Medicine
-
Journal of Neurobiology and Genetics
-
Medical Imaging and Nuclear Medicine
-
Bacterial Genetics and Ecology
-
Transactions on Cancer
-
Journal of Biophysics and Ecology
-
Journal of Animal Science and Veterinary
-
Academic Journal of Biochemistry and Molecular Biology
-
Transactions on Cell and Developmental Biology
-
Rehabilitation Engineering & Assistive Technology
-
Orthopaedics and Sports Medicine
-
Hematology and Stem Cell
-
Journal of Intelligent Informatics and Biomedical Engineering
-
MEDS Basic Medicine
-
MEDS Stomatology
-
MEDS Public Health and Preventive Medicine
-
Journal of Enzyme Engineering
-
Advances in Industrial Pharmacy and Pharmaceutical Sciences
-
Bacteriology and Microbiology
-
Advances in Physiology and Pathophysiology
-
Journal of Vision and Ophthalmology
-
Frontiers of Obstetrics and Gynecology
-
Digestive Disease and Diabetes
-
Advances in Immunology and Vaccines
-
Nanomedicine and Drug Delivery
-
Cardiology and Vascular System
-
Pediatrics and Child Health
-
Journal of Reproductive Medicine and Contraception
-
Journal of Respiratory and Lung Disease
-
Journal of Bioinformatics and Biomedicine